In the first phase III efficacy trial of the malaria vaccine SPf66 in Africa, MOIs in SPf66-and placebo-vaccinated children were analyzed by polymerase chain reaction -restriction fragment length polymorphism of the Plasmodium falciparum merozoite surface antigen 2 (MSA2). MOIs were significantly reduced in asymptomatic vaccine recipients compared with those in asymptomatic placebo recipients; however, no differences were observed among symptomatic children in the vaccine and control groups. These results show that immunization with SPf66 modulates the course of naturally occurring infections, as reflected by reduced MOIs. In placebo recipients, however, there was a significant negative correlation between numbers of infecting genotypes, as identified by MSA2, and morbidity. Asymptomatic placebo recipients had an average of 5 concurrent infections, whereas children with clinical cases had an average of 3.4 infections. These data provide further evidence that premunition from concurrent infections is important in immunity against clinical malaria. No such effect of multiple infections was found in the vaccinated group.
The malaria vaccine SPf66 has been extensively tested in to be highly polymorphic, yet all identified alleles could be grouped into the two allelic families, FC27 and 3D7 [8] . South American populations, with a variable degree of efficacy against clinical Plasmodium falciparum malaria [1] . In phase MSA2 is a useful marker in studies of diversity in Plasmodium populations and has been used in several other studies III trials against clinical malaria, the vaccine had an efficacy of 39% in Colombia [2] , 55% in Venezuela [3] , and 66%
in an attempt to describe parasite diversity within endemic populations [9 -12] . We recently reported different age distriin Ecuador [4] , three countries with low malaria endemicity. Recently, SPf66 was tested in children and infants in malariabutions of the two allelic families of MSA2 in a malariaexposed population in Papua New Guinea [10] . However, since endemic areas of Africa. The vaccine had an estimated protective efficacy of 31% against clinical episodes in 1-to 5-yearmultiple infections are relatively infrequent in Papua New Guinea, only limited investigation of the effects of MOIs on old Tanzanian children in an area where malaria transmission is intense and perennial [5] . In The Gambia, no significant parasite density and morbidity was possible. From studies conducted in areas with different endemicity, protection was observed in a trial involving infants who were 6 -11 months old at the time of the first vaccine dose and it appears that numbers and multiplicity of concurrent P. falciparum infections as determined by MSA2 analysis could be who were exposed to seasonal malaria [6] . The African trials, however, were not completely comparable, primarily because markers for exposure [10 -13] . In hyperendemic areas, such as Senegal or Tanzania, multiple infections have been observed of the different endemicity situations but also due to trial designs [6] . A recent SPf66 trial in northwestern Thailand also with high frequencies, and MOIs were high [13, 14] . In holoendemic areas, such as lowland areas of Papua New Guinea, showed no vaccine efficacy [7] .
To analyze the effect of vaccination with SPf66 on parasite multiple infections were observed less frequently, and multiplicity was low [10, 15, 16] . In this study, we investigated P. diversity and MOI, we genotyped P. falciparum infections from vaccine and placebo recipients from the Tanzanian trial for the falciparum MOIs in vaccine and placebo recipients. merozoite surface antigen 2 (MSA2). MSA2 has been shown
Material and Methods
Samples. Samples described in this study were collected dur- Received 12 April 1996; revised 16 October 1996. ing a phase III randomized trial of the SPf66 malaria vaccine in All experiments involving humans followed the guidelines of conduct of Idete village, Kilombero District, Tanzania [5] . Details of the trial clinical research and were performed after informed consent of the children's design have been presented elsewhere [17] . In brief, children who parents or guardians. Research and ethical clearance was granted by the Tanzawere 1 to 5 years old at the time of the first dose of placebo or (table 2) . Twelve crossing-overs controls were also selected to have the same age distributions as between MSA2 alleles of different allelic families as described cases. However, because clinical malaria occurred predominantly by Ntoumi et al. [13] and Marshall et al. [22] were detected in the youngest children [19] , it was not possible to select enough by recombination of the family-specific restriction fragments. showed a significant reduction of MOIs. In vaccinated children, the DNA was amplified by polymerase chain reaction (PCR), using the mean number of concurrent infections was 3.9/sample, and the primers S2/S3 and S1/S4 for primary and nested PCR, respecin placebo recipients it was 5.0/sample (P Å .005, Wilcoxon tively [20] . The PCR products subsequently were subjected to an Z Å 2.84). A reduction was also seen for the individual allelic array of restriction enzymes, and the resulting fragments were families (table 2) . In contrast, in clinical cases the mean number separated on 12% polyacrylamide gels as described [21] . Å .005). There was no association with 3D7-like infections and densities in asymptomatic vaccinees or placebo recipients, suggesting that these infections generally made only a small Results contribution to the overall density. These findings were not significantly affected by adjustment for age of the child or for In total, 282 samples were genotyped for MSA2. Table 1 provides demographic and parasitologic data for the children the survey at which the sample was collected. When asymptomatic and symptomatic placebo recipients included in this analysis.
MSA2 was genotyped by PCR-RFLP in 135 samples from were compared, however, a strong negative association between risk of clinical malaria and the numbers of simultanevaccinated children and in 147 samples from placebo recipients. After treatment with sulfadoxine-pyrimethamine, which ously infecting different parasites was observed, a finding that could not be accounted for by age or time trends. A logistic was required in the trial design, the MOIs showed a very rapid / 9d21$$ap23 02-24-97 19:25:57 jinfa UC: J Infect regression model was used to estimate the risk of being cliniIn contrast, no significant difference in numbers of infections was observed among symptomatic and asymptomatic vaccically ill with malaria with multiple simultaneous infections. Curves were fitted for all MSA2 genotypes, for 3D7-like infecnated children (table 2) , and the risk of clinical episodes did not vary with the number of simultaneous infections, as detertions only, and for FC27-like genotypes only (figure 2). The similar gradients of the curves suggested that multiplicity, not mined by MSA2 PCR (logistic regression: likelihood ratio x 1 2 Å 0.29, P Å .59) (figure 2). any allelic family of the merozoite surface antigen, confers protection. However, the statistical significance of the regression was greater for 3D7-like genotypes (likelihood ratio x 2 Å Discussion 18.7, P õ .001), due to the considerably larger diversity of this allelic family, than for FC27-like genotypes (x 2 Å 6.8, For the present study, 282 children who were 1 -5 years old at the beginning of the study and living in an area of intense P Å .009), which displayed a smaller diversity. malaria transmission were analyzed for infecting parasite genoa high multiplicity of P. falciparum infections in this area [14] . Similar MOIs determined by use of a different technique were types. Infections with an average of 5 different genotypes were identified in asymptomatic placebo recipients, using highly senrecently reported from Senegal [12, 13] . The MOIs and frequency of multiple infections were much higher than those in sitive PCR-RFLP for MSA2. In contrast, infections with only 3.9 MSA2 genotypes were identified in asymptomatic vaccine studies conducted in Papua New Guinea using the identical method [10, 15] , likely as a consequence of the higher exposure recipients. These data confirm previous results demonstrating In vaccinated children, MOIs were significantly reduced. nated children is that a high MOI provides protection per se.
In support of our interpretation, a recent study in Papua New The reduction of multiplicity in asymptomatic P. falciparum infections associated with SPf66 vaccination seems to be comGuinea, in which the prospective risk of clinical malaria was analyzed in relation to multiple infections, showed that children parable in magnitude to the effects on clinical episodes [5] and on parasite densities [19] . There was no reduction in the with multiple infections had a lower prospective risk of clinical malaria (Al-Yaman F, personal communication). There is eviincidence of blood-stage infection after three doses of vaccine [5] , and SPf66 did not significantly reduce the overall prevadence that clinical malaria in children in endemic areas occurs as a result of acquisition of a parasite with an antigen genotype lence of infection in the Tanzanian trial [19] . Hence, the reduced MOI in asymptomatic infections is likely to be a conseto which they do not yet have immunity [16, 28] . As a child ages, the repertoire of genotypes to which the immune system quence of an increased rate of elimination of individual infections. This would correspond to the reported results of the has been exposed increases, and thus the child becomes more likely to be protected against any new infections [29]. early SPf66 challenge trials [24, 25] in nonimmune hosts, which indicated that SPf66 does not induce sterilizing immu-
The results of the present study in placebo recipients suggest that it is not only memory of previous infections but also nity against P. falciparum but that some infections can be selflimiting. It appears that this course may also be followed by that the repertoire of concurrent infections (premunition) may determine the specificity of effective immune mechanisms individual infections in children with considerable previous exposure and with multiple infections of parasites with different against new infections [30] . It appears that the process of acquisition of premunition is probably highly dependent on the degenotypes.
The observed differences in multiplicity between vaccine gree of endemicity and on the number of infective bites an individual receives. Immunologic cross-protection between difand placebo recipients may be explained by an immune modulation due to vaccination. In the absence of vaccination, lowferent genotypes may also increase the acquisition of immunity. In contrast to findings in the placebo recipients, the number density malaria infections can persist because natural immunity to asexual stage parasites appears to be highly density-depenof infections in vaccine recipients with clinical malaria was very similar to that in asymptomatic vaccine recipients. Vaccident [23, 24]: The immune system is predominantly stimulated by high-density infections, and low-grade parasitemia may be nation with SPf66 had apparently eliminated the effect of multiple infections. This may be explained by differences in the tolerated. In semi-immune persons, the densities of many infections may thus be reduced to a low level, but infection is not course of an infection in vaccinated children, in whom the acquisition of multiple infections may be slower and the elimicompletely eliminated. Unlike naturally stimulated immunity, vaccine-induced immunity is in general not density-dependent nation of infections seems to be faster than in placebo recipients. But if immunity against individual genotypes takes some (i.e., the primary response does not depend on the intensity or even on the existence of an infection). Our results with vaccine time to develop, the reduced duration of infections could interfere with the development of premunition. Presumably, this recipients suggest that SPf66 may induce a response sufficient to control high-density infections and hence to prevent morbidmust be compensated for by the vaccine-induced protective effect to control high-density parasitemia. ity while eliminating low-grade infections. This could result in the observed reduction of MOIs in both groups.
The possibility that the vaccine is specifically more active against certain genotypes and that other genotypes gradually The significant negative correlation between MOIs and morbidity in placebo recipients is in agreement with findings from accumulate must therefore still be considered, although to date no significant differences in MSA2 genotype frequencies Papua New Guinea, where multiple infections were associated with a reduced risk of clinical malaria [15] . One explanation for have been observed (data not shown). Due to the large polymorphism of MSA2, identification of a shift in allele frequenthese findings could be that in clinical malaria episodes, the dominant parasite genotype may stimulate a complex cascade of cies at this locus would require large sample sizes. The possible selection for resistant genotypes in a vaccinated population nonspecific responses, such as cytokine-mediated fever and release of nitric oxide or oxygen radicals, which have an antiparamust be considered and should be a priority question for further investigation, which also should include additional sitic effect [26, 27] , eliminating nondominant genotypes or suppressing them below the PCR detection limit. This would result polymorphic markers. in a significantly reduced MOI. Reduced multiplicity in children with clinical episodes could have also been due to more frequent
